Page 2
-
FDA approves generic Truvada — but there’s a catch
The move took advocates by surprise, since it wasn’t expected until 2021. However, the announcement has led to confusion about how soon it might be available.
-
Report: Drug maker was focused on profits, not patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease.
-
FDA rejects two HIV drugs from Gilead Sciences
FOSTER CITY, Calif. — Gilead Sciences Inc. said Monday that the Food and Drug Administration rejected two marketing applications for HIV treatments, citing quality control problems at the company’s manufacturing facilities.